رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06136624 (OMAHA-003) لـ سرطان البروستاتا النقيلي هي يقبل مشاركين. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
العودة إلى البحث
ميرك آند كوStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) المرحلة الثالثة ١٬٣١٠ عشوائية تجربة مفتوحة البقاء الكلي
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ رادار التجارب AI مساعدتك؛ ما عليك سوى النقر على «وصف الدراسة» لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06136624 (OMAHA-003) مصممة لدراسة علاج لـسرطان البروستاتا النقيلي. إنها تجربة تدخُّلية من المرحلة الثالثة وهي يقبل مشاركين. بدأت في ١٨ جمادى الآخرة ١٤٤٥ هـ مع خطة لتجنيد ١٬٣١٠ مشاركًا. تقودها ميرك آند كو، ومن المتوقع اكتمالها بحلول ١١ ربيع الأول ١٤٥٠ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ١ شوال ١٤٤٧ هـ.
الملخص
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to...عرض المزيد
العنوان الرسمي
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
الحالات الطبية
سرطان البروستاتا النقيليالمنشورات
مقالات علمية وأوراق بحثية منشورة حول هذه التجربة السريرية:معرّفات دراسة أخرى
- OMAHA-003
- 5684-003
- 2023-504899-25-00 (معرف آخر) (EU CT)
- MK-5684-003 (معرف آخر) (MSD)
- jRCT2031240029 (معرف السجل) (Japan Registry of Clinical Trials (jRCT))
- U1111-1287-5304 (معرف السجل) (UTN)
NCT معرّف
تاريخ البدء (فعلي)
2023-12-31
آخر تحديث مُنشور
2026-03-20
تاريخ الاكتمال (المقدر)
2028-08-02
عدد المشاركين المخطط لهم
١٬٣١٠
نوع الدراسة
تدخُّلية
المرحلة
المرحلة الثالثة
الحالة
يقبل مشاركين
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
لا شيء (تجربة مفتوحة)
مجموعات/التدخلات
| مجموعة المشاركين/الذراع | التدخل/العلاج |
|---|---|
تجريبيةOpevesostat Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication. | Opevesostat Administered orally Hydrocortisone Administered orally or IM as a rescue medication Fludrocortisone acetate Administered orally Dexamethasone Administered orally as rescue medication |
مقارن نشطAbiraterone Acetate or Enzalutamide Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets. | أسيتات الأبيراتيرون Administered orally Enzalutamide Administered orally Prednisone Administered orally |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~54 months |
OS in AR LBD Mutation-Negative Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-negative participants will be reported for each study arm. | Up to ~54 months |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review in AR LBD Mutation-Positive Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
rPFS Per Prostate Cancer Working Group-modifiedRECIST 1.1 as Assessed by Blinded Independent Central Review in AR LBD Mutation-Negative Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
Time to Initiation of the First Subsequent Anti-Cancer Therapy or Death (TFST) | TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. | Up to ~54 months |
Objective Response (OR) | OR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Duration of Response (DOR) | DOR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Time to Pain Progression (TTPP) | TTPP is assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and opiate analgesic use (Analgesic Quantification Algorithm \[AQA\] Score). | Up to ~54 months |
Time to Prostate-specific Antigen (PSA) Progression | The time from randomization to PSA progression. The PSA progression date is defined as the date of either: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. | Up to ~54 months |
Time to First Symptomatic Skeletal-related Event (SSRE) | The time from randomization to the first occurrence of any of the following symptomatic skeletal-related events: 1) Use of EBRT to prevent or relieve skeletal symptoms; 2) new symptomatic pathologic bone fracture (vertebral or nonvertebral); 3) spinal cord compression; or 4) tumor-related orthopedic surgical intervention. | Up to ~54 months |
Number of Participants Who Experience an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
مساعد المشاركة
معايير الأهلية
الأعمار المؤهلة للدراسة
طفل, بالغ, كبار السن
الجنس المؤهل
الكل
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
- Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
- Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
- Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
- Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<1.7 nM)
- Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
- Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
- Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment
- Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment
- If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression >4 weeks since the last flutamide treatment and >6 weeks since the last bicalutamide or nilutamide treatment
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization
- Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.
- Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom
- Has a gastrointestinal disorder that might affect absorption
- Has a history of pituitary dysfunction
- Has poorly controlled diabetes mellitus
- Has clinically significant abnormal serum potassium or sodium level
- Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
- Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
- Has a history of clinically significant ventricular arrhythmias
- Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
- Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications
- Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization
- Has received radium-223 or lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or lutetium-177 administered more than 4 weeks before the date of randomization
- Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization
- Has received colony-stimulating factors within 28 days before the date of randomization
- Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization
- Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks
- Has a "superscan" bone scan
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has an active infection requiring systemic therapy
- Has concurrent active HBV or known active HCV infection
- Has a history of long QTc syndrome
- Has any of the following at Screening Visit: hypotension (systolic BP <110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy)
- Is unable to swallow capsules/tablets
- Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures
- Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
- Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong CYP3A4 inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle \[Silybum marianum\])
- Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention
ميرك آند كو707 تجارب سريرية نشطة للاستكشافأوريون كوربوريشن9 تجارب سريرية نشطة للاستكشافجهة اتصال مركزية للدراسة
جهة اتصال: Toll Free Number, 1-888-577-8839, [email protected]
281 مواقع الدراسة في 36 بلدان
California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California, 92868, United States
نشط (لا يقبل مشاركين جدد)
Stanford Cancer Center ( Site 0036), Palo Alto, California, 94304, United States
Study Coordinator, جهة اتصال, 650-725-2078
يقبل مشاركين
Kaiser Permanente Riverside Medical Center ( Site 0099), Riverside, California, 92505, United States
Study Coordinator, جهة اتصال, 951-809-8361
يقبل مشاركين
Colorado
Anschutz Cancer Pavilion ( Site 0046), Aurora, Colorado, 80045, United States
Study Coordinator, جهة اتصال, 302-290-3598
يقبل مشاركين
University of Colorado Health - Highlands Ranch Hospital ( Site 0111), Highlands Ranch, Colorado, 80129, United States
Study Coordinator, جهة اتصال, 302-290-3598
يقبل مشاركين
Colorado Clinical Research ( Site 0067), Lakewood, Colorado, 80228, United States
نشط (لا يقبل مشاركين جدد)
University of Colorado Health - Lone Tree Medical Center ( Site 0112), Lone Tree, Colorado, 80124, United States
Study Coordinator, جهة اتصال, 720-848-5146
يقبل مشاركين
Connecticut
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven, Connecticut, 06510, United States
Study Coordinator, جهة اتصال, 203-737-8076
يقبل مشاركين
Florida
Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida, 33901, United States
Study Coordinator, جهة اتصال, 727-364-9201
يقبل مشاركين
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082), Miami, Florida, 33125, United States
نشط (لا يقبل مشاركين جدد)
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051), Miami, Florida, 33136, United States
Study Coordinator, جهة اتصال, 305-243-1543
يقبل مشاركين
Illinois
University of Illinois at Chicago ( Site 0105), Chicago, Illinois, 60612, United States
Study Coordinator, جهة اتصال, 973-330-2391
يقبل مشاركين
University of Chicago Medical Center ( Site 0045), Chicago, Illinois, 60637, United States
Study Coordinator, جهة اتصال, 773-702-7609
يقبل مشاركين
Iowa
University of Iowa ( Site 0047), Iowa City, Iowa, 52242, United States
Study Coordinator, جهة اتصال, 319-353-8155
يقبل مشاركين
Kentucky
University of Kentucky Chandler Medical Center ( Site 0048), Lexington, Kentucky, 40536, United States
نشط (لا يقبل مشاركين جدد)
Louisiana
Ochsner Clinic Foundation ( Site 0108), New Orleans, Louisiana, 70121, United States
نشط (لا يقبل مشاركين جدد)
Maryland
Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore, Maryland, 21201, United States
Study Coordinator, جهة اتصال, 410-707-4011
يقبل مشاركين
Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore, Maryland, 21201, United States
Study Coordinator, جهة اتصال, 410-707-4011
يقبل مشاركين
Michigan
Henry Ford Hospital ( Site 0015), Detroit, Michigan, 48202, United States
نشط (لا يقبل مشاركين جدد)
Minnesota
M Health Fairview Clinics and Surgery Center ( Site 0019), Minneapolis, Minnesota, 55455, United States
Study Coordinator, جهة اتصال, 612-626-1422
يقبل مشاركين
Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota, 55416, United States
Study Coordinator, جهة اتصال, 952-993-3252
يقبل مشاركين
Missouri
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062), St Louis, Missouri, 63110, United States
نشط (لا يقبل مشاركين جدد)
Nebraska
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095), Omaha, Nebraska, 68105, United States
Study Coordinator, جهة اتصال, 402-559-8500
يقبل مشاركين
Nevada
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada, 89148, United States
Study Coordinator, جهة اتصال, 702-952-1251
يقبل مشاركين
New Jersey
Atlantic Health System Morristown Medical Center ( Site 0115), Morristown, New Jersey, 07960, United States
Study Coordinator, جهة اتصال, 973-971-7960
يقبل مشاركين
Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey, 08901, United States
نشط (لا يقبل مشاركين جدد)
New York
James J. Peters VA Medical Center ( Site 0088), The Bronx, New York, 10468, United States
Study Coordinator, جهة اتصال, 718-584-9000
يقبل مشاركين
Ohio
University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio, 44106, United States
Study Coordinator, جهة اتصال, 216-844-3951
يقبل مشاركين
Oregon
Oregon Health and Science University ( Site 0028), Portland, Oregon, 97239, United States
نشط (لا يقبل مشاركين جدد)
VA Portland Health Care System ( Site 0058), Portland, Oregon, 97239, United States
Study Coordinator, جهة اتصال, 503-220-8262
يقبل مشاركين
Pennsylvania
AHN Allegheny General Hospital ( Site 0001), Pittsburgh, Pennsylvania, 15212, United States
نشط (لا يقبل مشاركين جدد)
South Carolina
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina, 29401, United States
نشط (لا يقبل مشاركين جدد)
South Dakota
Avera Cancer Institute - Pierre ( Site 0118), Pierre, South Dakota, 57501, United States
Study Coordinator, جهة اتصال, 605-224-3370
يقبل مشاركين
Avera Cancer Institute- Research ( Site 0094), Sioux Falls, South Dakota, 57105, United States
Study Coordinator, جهة اتصال, 605-322-6900
يقبل مشاركين
Avera Cancer Institute - Yankton ( Site 0117), Yankton, South Dakota, 57078, United States
Study Coordinator, جهة اتصال, 605-655-1800
يقبل مشاركين
Tennessee
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, 37203, United States
Study Coordinator, جهة اتصال, 615-218-4647
يقبل مشاركين
Texas
Texas Oncology - Central/South Texas ( Site 8003), Austin, Texas, 78731, United States
Study Coordinator, جهة اتصال, 512-427-9400
يقبل مشاركين
Texas Oncology - DFW ( Site 8001), Dallas, Texas, 75246, United States
نشط (لا يقبل مشاركين جدد)
Texas Oncology - Gulf Coast ( Site 8002), The Woodlands, Texas, 77380, United States
Study Coordinator, جهة اتصال, 713-467-1722
يقبل مشاركين
Virginia
University of Virginia Health System ( Site 0054), Charlottesville, Virginia, 22908, United States
Study Coordinator, جهة اتصال, 434-327-3029
يقبل مشاركين
VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond, Virginia, 23219, United States
نشط (لا يقبل مشاركين جدد)
Blue Ridge Cancer Care ( Site 0004), Roanoke, Virginia, 24014, United States
Study Coordinator, جهة اتصال, 540-982-0237
يقبل مشاركين
Washington
Fred Hutchinson Cancer Center ( Site 0013), Seattle, Washington, 98109, United States
Study Coordinator, جهة اتصال, 617-413-9079
يقبل مشاركين
Wisconsin
MEDICAL COLLEGE OF WISCONSIN ( Site 0020), Milwaukee, Wisconsin, 53226, United States
Study Coordinator, جهة اتصال, 414-805-4600
يقبل مشاركين
Buenos Aires
Hospital Británico de Buenos Aires-Oncology ( Site 0202), Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina
Study Coordinator, جهة اتصال, 1143096839
يقبل مشاركين
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires, B7600FZO, Argentina
Study Coordinator, جهة اتصال, 02234963224
يقبل مشاركين
Buenos Aires F.D.
Instituto Alexander Fleming-Alexander Fleming ( Site 0206), Buenos Aires, Buenos Aires F.D., 1426ANZ, Argentina
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Santa Fe Province
Sanatorio Parque ( Site 0208), Rosario, Santa Fe Province, S2000DVC, Argentina
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Hospital Aleman-Oncology ( Site 0207), Buenos Aires, C1118AAT, Argentina
Study Coordinator, جهة اتصال, 01148277000
يقبل مشاركين
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204), Mendoza, M5500AYB, Argentina
نشط (لا يقبل مشاركين جدد)
New South Wales
Dubbo Hospital ( Site 0235), Dubbo, New South Wales, 2830, Australia
Study Coordinator, جهة اتصال, 0268096200
يقبل مشاركين
Macquarie University-MQ Health Clinical Trials Unit ( Site 0234), Macquarie University, New South Wales, 2109, Australia
Study Coordinator, جهة اتصال, 0298122979
يقبل مشاركين
Westmead Hospital ( Site 0232), Westmead, New South Wales, 2145, Australia
نشط (لا يقبل مشاركين جدد)
Queensland
Princess Alexandra Hospital-Cancer Care Serices ( Site 0237), Brisbane, Queensland, 4102, Australia
Study Coordinator, جهة اتصال, +6173176 9289
يقبل مشاركين
Victoria
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230), Melbourne, Victoria, 3000, Australia
نشط (لا يقبل مشاركين جدد)
Styria
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280), Graz, Styria, 8036, Austria
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Upper Austria
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276), Linz, Upper Austria, 4020, Austria
Study Coordinator, جهة اتصال, +4373276774724
يقبل مشاركين
Klinikum Wels-Grieskirchen GmbH ( Site 0279), Wels, Upper Austria, 4600, Austria
Study Coordinator, جهة اتصال, +4372424152328
يقبل مشاركين
Espírito Santo
Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320), Vitória, Espírito Santo, 29041-295, Brazil
نشط (لا يقبل مشاركين جدد)
Estado de Bahia
Obras Sociais Irma Dulce ( Site 0302), Salvador, Estado de Bahia, 40415-006, Brazil
نشط (لا يقبل مشاركين جدد)
Minas Gerais
Hospital Felicio Rocho ( Site 0317), Belo Horizonte, Minas Gerais, 30110-934, Brazil
نشط (لا يقبل مشاركين جدد)
Hospital Mario Penna ( Site 0309), Belo Horizonte, Minas Gerais, 30380-472, Brazil
نشط (لا يقبل مشاركين جدد)
Paraná
Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314), Curitiba, Paraná, 80440-220, Brazil
نشط (لا يقبل مشاركين جدد)
Santa Catarina
Clínica de Neoplasias Litoral ( Site 0305), Itajaí, Santa Catarina, 88301-220, Brazil
Study Coordinator, جهة اتصال, +5547984046243
يقبل مشاركين
São Paulo
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308), Bragança Paulista, São Paulo, 12916-542, Brazil
نشط (لا يقبل مشاركين جدد)
A. C. Camargo Cancer Center ( Site 0310), São Paulo, São Paulo, 01509-010, Brazil
نشط (لا يقبل مشاركين جدد)
Alberta
Cross Cancer Institute ( Site 0332), Edmonton, Alberta, T6G 1Z2, Canada
Study Coordinator, جهة اتصال, 7804328762
يقبل مشاركين
Ontario
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336), Ottawa, Ontario, K1H 8L6, Canada
Study Coordinator, جهة اتصال, 613-737-7700
يقبل مشاركين
Sunnybrook Research Institute ( Site 0331), Toronto, Ontario, M4N 3M5, Canada
Study Coordinator, جهة اتصال, 647-533-1023
يقبل مشاركين
Princess Margaret Cancer Centre ( Site 0330), Toronto, Ontario, M5G 2M9, Canada
Study Coordinator, جهة اتصال, (416) 946-4501
يقبل مشاركين
Quebec
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328), Greenfield Park, Quebec, J4V 2H1, Canada
Study Coordinator, جهة اتصال, 4504665000 ext 3226
يقبل مشاركين
Centre Hospitalier de l'Université de Montréal ( Site 0326), Montreal, Quebec, H2X 3E4, Canada
نشط (لا يقبل مشاركين جدد)
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327), Québec, Quebec, G1J 1Z4, Canada
Study Coordinator, جهة اتصال, 418 525-4444
يقبل مشاركين
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329), Sherbrooke, Quebec, J1H 5H4, Canada
نشط (لا يقبل مشاركين جدد)
Coquimbo Region
IC La Serena Research ( Site 0356), La Serena, Coquimbo Region, 1720430, Chile
نشط (لا يقبل مشاركين جدد)
Los Ríos Region
Clinical Research Chile SpA ( Site 0358), Valdivia, Los Ríos Region, 5110683, Chile
نشط (لا يقبل مشاركين جدد)
Maule Region
Clinica Universidad Catolica del Maule-Oncology ( Site 0355), Talca, Maule Region, 3465584, Chile
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Region M. de Santiago
FALP ( Site 0353), Santiago, Region M. de Santiago, 7500921, Chile
نشط (لا يقبل مشاركين جدد)
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354), Santiago, Region M. de Santiago, 8330024, Chile
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Bradfordhill-Clinical Area ( Site 0351), Santiago, Region M. de Santiago, 8420383, Chile
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Bradford Hill Norte ( Site 0357), Antofagasta, 1240000, Chile
نشط (لا يقبل مشاركين جدد)
Anhui
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui, 230000, China
Study Coordinator, جهة اتصال, +86 02782201756
يقبل مشاركين
Beijing Municipality
Peking University First Hospital-Urology ( Site 0390), Beijing, Beijing Municipality, 100034, China
Study Coordinator, جهة اتصال, +86 (010) 64008229
يقبل مشاركين
Beijing Friendship Hospital Affiliate of Capital University ( Site 0396), Beijing, Beijing Municipality, 100050, China
Study Coordinator, جهة اتصال, +86(010)63138375
يقبل مشاركين
Beijing Cancer hospital-Urinary Surgery ( Site 0395), Beijing, Beijing Municipality, 100142, China
Study Coordinator, جهة اتصال, 86 010 8812 1122
يقبل مشاركين
Chongqing Municipality
The First Affiliated Hospital of Chongqing Medical University ( Site 0427), Chongqing, Chongqing Municipality, 400010, China
Study Coordinator, جهة اتصال, 023 89012012
يقبل مشاركين
Chongqing University Cancer Hospital ( Site 0416), Chongqing, Chongqing Municipality, 400030, China
Study Coordinator, جهة اتصال, 02365075629
يقبل مشاركين
Southwest Hospital of Third Military Medical University ( Site 0420), Chongqing, Chongqing Municipality, 400038, China
Study Coordinator, جهة اتصال, 023 68765878
يقبل مشاركين
Chongqing Three Gorges Central Hospital's ( Site 0426), Chongqing, Chongqing Municipality, 404100, China
Study Coordinator, جهة اتصال, 023 58103150
يقبل مشاركين
Fujian
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414), Fuzhou, Fujian, 350005, China
Study Coordinator, جهة اتصال, +86059187983333
يقبل مشاركين
The First Affiliated hospital of Xiamen University-Urology ( Site 0415), Xiamen, Fujian, 361003, China
Study Coordinator, جهة اتصال, 0592-2132222
يقبل مشاركين
Guangdong
The First Affiliated Hospital of Guangzhou Medical University ( Site 0412), Guangzhou, Guangdong, 510120, China
Study Coordinator, جهة اتصال, (020) 83062114
يقبل مشاركين
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413), Guangzhou, Guangdong, 511400, China
Study Coordinator, جهة اتصال, +8602087343533
يقبل مشاركين
Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 0407), Wuhan, Hubei, 430000, China
Study Coordinator, جهة اتصال, 027-83665555
يقبل مشاركين
Hubei Cancer Hospital-Urinary surgery ( Site 0406), Wuhan, Hubei, 430079, China
Study Coordinator, جهة اتصال, 8613907110640
يقبل مشاركين
Hunan
Hunan Cancer Hospital ( Site 0405), Changsha, Hunan, 410013, China
Study Coordinator, جهة اتصال, 073189762270
يقبل مشاركين
Jiangsu
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436), Huaian, Jiangsu, 223300, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377), Nanjing, Jiangsu, 210008, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Affiliated hospital of Jiangnan university ( Site 0434), Wuxi, Jiangsu, 214122, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Jiangxi
Jiangxi Cancer Hospital ( Site 0386), Nanchang, Jiangxi, 330029, China
Study Coordinator, جهة اتصال, 86079188317256
يقبل مشاركين
Shaanxi
The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394), Xi'an, Shaanxi, 710004, China
Study Coordinator, جهة اتصال, 029-87679000
يقبل مشاركين
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393), Xi'an, Shaanxi, 710061, China
Study Coordinator, جهة اتصال, 029-85323112
يقبل مشاركين
Shandong
Yantai Yuhuangding Hospital ( Site 0397), Yantai, Shandong, 264099, China
Study Coordinator, جهة اتصال, 86 0535 6691999
يقبل مشاركين
Shangai
Zhongshan Hospital of Fudan University (0430), Shanghai, Shangai, 200032, China
Jianming Guo, جهة اتصال, 13681971306, [email protected]
يقبل مشاركين
Shanghai Municipality
Fudan University Shanghai Cancer Center-Urology department ( Site 0376), Shanghai, Shanghai Municipality, 200000, China
Study Coordinator, جهة اتصال, 021-38196379
يقبل مشاركين
Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388), Shanghai, Shanghai Municipality, 200041, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Sichuan
The Third People's Hospital of Chengdu (CDTPH) ( Site 0428), Chengdu, Sichuan, 500643, China
Study Coordinator, جهة اتصال, 67566947
يقبل مشاركين
West China Hospital, Sichuan University-Urology Surgery ( Site 0417), Chengdu, Sichuan, 610041, China
Study Coordinator, جهة اتصال, +86028-85422114
يقبل مشاركين
Nanchong Central Hospital-urology ( Site 0422), Nanchong, Sichuan, 500643, China
Study Coordinator, جهة اتصال, 08172606822
يقبل مشاركين
Suining Central Hospital ( Site 0437), Suining, Sichuan, 629000, China
Study Coordinator, جهة اتصال, 08252292093
يقبل مشاركين
Tianjin Municipality
Tianjin Medical University Cancer Institute & Hospital ( Site 0392), Tianjin, Tianjin Municipality, 300060, China
Study Coordinator, جهة اتصال, +862223340123
يقبل مشاركين
The Second Hospital of Tianjin Medical University ( Site 0391), Tianjin, Tianjin Municipality, 300211, China
Study Coordinator, جهة اتصال, +8602288326748
يقبل مشاركين
Xinjiang
Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419), Ürümqi, Xinjiang, 830000, China
Study Coordinator, جهة اتصال, 86 09917819156
يقبل مشاركين
Yunnan
The Second Affiliated Hospital Of Kunming Medical University ( Site 0429), Kunming, Yunnan, 650033, China
Study Coordinator, جهة اتصال, 087165351281
يقبل مشاركين
Yunnan Province Cancer Hospital ( Site 0418), Kunming, Yunnan, 650107, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Zhejiang
Zhejiang Provincial People's Hospital-Urology ( Site 0378), Hangzhou, Zhejiang, 310014, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Zhejiang Cancer Hospital ( Site 0435), Hangzhou, Zhejiang, 310022, China
Study Coordinator, جهة اتصال, 0571-88122261
يقبل مشاركين
The First Hospital of Jiaxing-urology ( Site 0380), Jiaxing, Zhejiang, 314001, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
The First Affiliated Hospital of Ningbo University ( Site 0383), Ningbo, Zhejiang, 315010, China
Study Coordinator, جهة اتصال, 86057487085588
يقبل مشاركين
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379), Wenzhou, Zhejiang, 325000, China
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Bogota D.C.
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501), Bogotá, Bogota D.C., 111321, Colombia
نشط (لا يقبل مشاركين جدد)
Cesar Department
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502), Valledupar, Cesar Department, 200001, Colombia
نشط (لا يقبل مشاركين جدد)
Departamento de Córdoba
IMAT S.A.S ( Site 0504), Montería, Departamento de Córdoba, 230002, Colombia
نشط (لا يقبل مشاركين جدد)
Santander Department
Fundación Cardiovascular de Colombia ( Site 0503), Piedecuesta, Santander Department, 681017, Colombia
نشط (لا يقبل مشاركين جدد)
Valle del Cauca Department
Fundación Valle del Lili ( Site 0505), Cali, Valle del Cauca Department, 760032, Colombia
نشط (لا يقبل مشاركين جدد)
Clínica Imbanaco S.A.S ( Site 0509), Cali, Valle del Cauca Department, 760042, Colombia
نشط (لا يقبل مشاركين جدد)
Brno-mesto
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553), Brno, Brno-mesto, 656 53, Czechia
Study Coordinator, جهة اتصال, +420 543 136 216
يقبل مشاركين
Moravskoslezský kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554), Ostrava, Moravskoslezský kraj, 708 52, Czechia
Study Coordinator, جهة اتصال, +420597372264
يقبل مشاركين
Olomoucký kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555), Olomouc, Olomoucký kraj, 779 00, Czechia
Study Coordinator, جهة اتصال, +420 588 444 699
يقبل مشاركين
Praha 5
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551), Prague, Praha 5, 150 06, Czechia
نشط (لا يقبل مشاركين جدد)
Capital Region
Rigshospitalet ( Site 0576), Copenhagen, Capital Region, 2100, Denmark
Study Coordinator, جهة اتصال, +45 35453545
يقبل مشاركين
Region Syddanmark
Odense Universitetshospital-Department of oncology ( Site 0579), Odense, Region Syddanmark, 5000, Denmark
نشط (لا يقبل مشاركين جدد)
Vejle Sygehus ( Site 0578), Vejle, Region Syddanmark, 7100, Denmark
Study Coordinator, جهة اتصال, +45 79405000
يقبل مشاركين
Northern Savonia
Kuopion Yliopistollinen Sairaala ( Site 0603), Kuopio, Northern Savonia, 70210, Finland
Study Coordinator, جهة اتصال, 35817173311
يقبل مشاركين
Pirkanmaa
Tampereen yliopistollinen sairaala ( Site 0604), Tampere, Pirkanmaa, 33520, Finland
Study Coordinator, جهة اتصال, 358331166811
يقبل مشاركين
Southwest Finland
Turku University Hospital-Department of Oncology ( Site 0601), Turku, Southwest Finland, 20520, Finland
Study Coordinator, جهة اتصال, 35823130729
يقبل مشاركين
Alsace
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627), Strasbourg, Alsace, 67200, France
Study Coordinator, جهة اتصال, +33368767207
يقبل مشاركين
Gard
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630), Nîmes, Gard, 30029, France
نشط (لا يقبل مشاركين جدد)
Ille-et-Vilaine
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632), Rennes, Ille-et-Vilaine, 35042, France
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Puy-de-Dome
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629), Clermont-Ferrand, Puy-de-Dome, 63003, France
Study Coordinator, جهة اتصال, +33473278005
يقبل مشاركين
Pyrenees-Atlantiques
Centre Hospitalier de la Côte Basque ( Site 0633), Bayonne, Pyrenees-Atlantiques, 64109, France
Study Coordinator, جهة اتصال, 33559443535
يقبل مشاركين
Val-de-Marne
Gustave Roussy ( Site 0626), Villejuif, Val-de-Marne, 94800, France
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Hôpital Européen Georges Pompidou ( Site 0628), Paris, 75015, France
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Bavaria
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696), Munich, Bavaria, 81675, Germany
نشط (لا يقبل مشاركين جدد)
Mecklenburg-Vorpommern
HELIOS Kliniken Schwerin ( Site 0694), Schwerin, Mecklenburg-Vorpommern, 19055, Germany
Study Coordinator, جهة اتصال, +493855202120
يقبل مشاركين
North Rhine-Westphalia
Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680), Bonn, North Rhine-Westphalia, 53127, Germany
Study Coordinator, جهة اتصال, +4922828714249
يقبل مشاركين
Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678), Münster, North Rhine-Westphalia, 48149, Germany
Study Coordinator, جهة اتصال, 0049251-8344658
يقبل مشاركين
Schleswig-Holstein
Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691), Lübeck, Schleswig-Holstein, 23538, Germany
Study Coordinator, جهة اتصال, +4945150043699
يقبل مشاركين
Thuringia
Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682), Jena, Thuringia, 07747, Germany
Study Coordinator, جهة اتصال, +49 3641 9 32 9947
يقبل مشاركين
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679), Berlin, 10117, Germany
Study Coordinator, جهة اتصال, 0049 30 450615297
يقبل مشاركين
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705), Hamburg, 20246, Germany
Study Coordinator, جهة اتصال, +4915222815585
يقبل مشاركين
Queen Mary Hospital ( Site 0727), Hong Kong, Hong Kong
Study Coordinator, جهة اتصال, +85222553838
يقبل مشاركين
Prince of Wales Hospital ( Site 0730), Shatin, Hong Kong
Study Coordinator, جهة اتصال, +85235052211
يقبل مشاركين
Bács-Kiskun county
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752), Kecskemét, Bács-Kiskun county, 6000, Hungary
Study Coordinator, جهة اتصال, +3676516719
يقبل مشاركين
Nógrád megye
Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761), Salgótarján, Nógrád megye, 3100, Hungary
Study Coordinator, جهة اتصال, +3632522000
يقبل مشاركين
Pest County
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756), Budapest, Pest County, 1122, Hungary
Study Coordinator, جهة اتصال, +36122486001171
يقبل مشاركين
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758), Debrecen, 4032, Hungary
Study Coordinator, جهة اتصال, +3652411717
يقبل مشاركين
Dublin
St. Vincent's University Hospital ( Site 0802), Dublin, Dublin, D04 T6F4, Ireland
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Tallaght University Hospital ( Site 0801), Dublin, D24 NR0A, Ireland
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Emek Medical Center ( Site 0830), Afula, 1834111, Israel
Study Coordinator, جهة اتصال, 0546708579
يقبل مشاركين
Rambam Health Care Campus-Oncology Division ( Site 0826), Haifa, 3109601, Israel
Study Coordinator, جهة اتصال, 04-7776234
يقبل مشاركين
Hadassah Medical Center ( Site 0833), Jerusalem, 9112001, Israel
Study Coordinator, جهة اتصال, 02-6777111
يقبل مشاركين
Meir Medical Center. ( Site 0832), Kfar Saba, 4428164, Israel
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Rabin Medical Center ( Site 0828), Petah Tikva, 4941492, Israel
Study Coordinator, جهة اتصال, 972-50-3745684
يقبل مشاركين
Sheba Medical Center ( Site 0827), Ramat Gan, 5265601, Israel
Study Coordinator, جهة اتصال, : +972-35302191
يقبل مشاركين
Emilia-Romagna
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879), Meldola, Emilia-Romagna, 47014, Italy
Study Coordinator, جهة اتصال, +390543739100
يقبل مشاركين
Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877), Milan, Lombardy, 20133, Italy
Study Coordinator, جهة اتصال, 00390223903033
يقبل مشاركين
Ospedale San Raffaele-Oncologia Medica ( Site 0876), Milan, 20132, Italy
Study Coordinator, جهة اتصال, +390226435668
يقبل مشاركين
Chiba
Toho University Sakura Medical Center ( Site 0906), Sakura, Chiba, 285-8741, Japan
Study Coordinator, جهة اتصال, +81434628811
يقبل مشاركين
Ehime
Ehime University Hospital ( Site 0918), Tōon, Ehime, 791-0295, Japan
Study Coordinator, جهة اتصال, +81-89-964-5111
يقبل مشاركين
Fukuoka
Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921), Kitakyushu, Fukuoka, 807-8556, Japan
نشط (لا يقبل مشاركين جدد)
Kurume University Hospital ( Site 0920), Kurume, Fukuoka, 830-0011, Japan
Study Coordinator, جهة اتصال, +81-942-35-3311
يقبل مشاركين
Hokkaido
Asahikawa Medical University Hospital ( Site 0901), Asahikawa, Hokkaido, 078-8510, Japan
Study Coordinator, جهة اتصال, +81-166-65-2111
يقبل مشاركين
Sapporo Medical University Hospital ( Site 0902), Sapporo, Hokkaido, 060-8543, Japan
Study Coordinator, جهة اتصال, +81-11-611-2111
يقبل مشاركين
Hokkaido University Hospital ( Site 0931), Sapporo, Hokkaido, 060-8648, Japan
Study Coordinator, جهة اتصال, +81117161161
يقبل مشاركين
Hyōgo
Kobe University Hospital ( Site 0914), Kobe, Hyōgo, 650-0017, Japan
Study Coordinator, جهة اتصال, +81783825111
يقبل مشاركين
Ishikawa-ken
Kanazawa Medical University Hospital ( Site 0909), Mukai-awagasaki, Ishikawa-ken, 920-0265, Japan
Study Coordinator, جهة اتصال, +81-76-286-3511
يقبل مشاركين
Kagawa-ken
Kagawa University Hospital ( Site 0917), Kita, Kagawa-ken, 761-0701, Japan
Study Coordinator, جهة اتصال, +81878985111
يقبل مشاركين
Kanagawa
Yokohama City University Medical Center ( Site 0908), Yokohama, Kanagawa, 232-0024, Japan
Study Coordinator, جهة اتصال, +81452615656
يقبل مشاركين
Nagasaki
National Hospital Organization Nagasaki Medical Center ( Site 0923), Ōmura, Nagasaki, 856-8562, Japan
Study Coordinator, جهة اتصال, +81-957-52-3121
يقبل مشاركين
Nara
Nara Medical University Hospital ( Site 0915), Kashihara, Nara, 634-8522, Japan
نشط (لا يقبل مشاركين جدد)
Okinawa
Nanbu Tokushukai Hospital ( Site 0930), Shimajiri, Okinawa, 901-0417, Japan
Study Coordinator, جهة اتصال, +81-98-998-3221
يقبل مشاركين
Osaka
Kansai Medical University Hospital ( Site 0912), Hirakata, Osaka, 573-1191, Japan
Study Coordinator, جهة اتصال, +81-72-804-0101
يقبل مشاركين
Bell Land General Hospital ( Site 0913), Sakai, Osaka, 599-8247, Japan
Study Coordinator, جهة اتصال, +81722342001
يقبل مشاركين
The University of Osaka Hospital ( Site 0911), Suita, Osaka, 565-0871, Japan
Study Coordinator, جهة اتصال, +81668795111
يقبل مشاركين
Saga-ken
Saga-Ken Medical Centre Koseikan ( Site 0922), Saga, Saga-ken, 840-8571, Japan
نشط (لا يقبل مشاركين جدد)
Tokyo
The Jikei University Hospital ( Site 0907), Minato, Tokyo, 105-8471, Japan
نشط (لا يقبل مشاركين جدد)
Akita University Hospital ( Site 0904), Akita, 010-8543, Japan
Study Coordinator, جهة اتصال, +81188341111
يقبل مشاركين
Kyushu University Hospital ( Site 0919), Fukuoka, 812-8582, Japan
Study Coordinator, جهة اتصال, +81926411151
يقبل مشاركين
Fukushima Medical University Hospital ( Site 0933), Fukushima, 960-1295, Japan
Study Coordinator, جهة اتصال, +81245471111
يقبل مشاركين
Gifu University Hospital ( Site 0910), Gifu, 501-1112, Japan
Study Coordinator, جهة اتصال, +81-58-230-6000
يقبل مشاركين
Hiroshima University Hospital ( Site 0916), Hiroshima, 734-8551, Japan
Study Coordinator, جهة اتصال, +81-82-257-5555
يقبل مشاركين
Kagoshima University Hospital ( Site 0929), Kagoshima, 890-8520, Japan
Study Coordinator, جهة اتصال, +81-99-275-5111
يقبل مشاركين
National Hospital Organization Kumamoto Medical Center ( Site 0924), Kumamoto, 860-0008, Japan
Study Coordinator, جهة اتصال, +81963536501
يقبل مشاركين
Miyazaki Prefectural Miyazaki Hospital ( Site 0927), Miyazaki, 880-8510, Japan
Study Coordinator, جهة اتصال, +81985244181
يقبل مشاركين
University of Miyazaki Hospital ( Site 0926), Miyazaki, 889-1692, Japan
Study Coordinator, جهة اتصال, +81-98-585-1510
يقبل مشاركين
Nagano Municipal Hospital ( Site 0932), Nagano, 381-8551, Japan
Study Coordinator, جهة اتصال, +81-26-295-1199
يقبل مشاركين
National Hospital Organization Oita Medical Center ( Site 0925), Ōita, 870-0263, Japan
نشط (لا يقبل مشاركين جدد)
Johor
Hospital Sultan Ismail ( Site 1081), Johor Bahru, Johor, 81100, Malaysia
Study Coordinator, جهة اتصال, +6073565155
يقبل مشاركين
Kuala Lumpur
University Malaya Medical Centre ( Site 1077), Lembah Pantai, Kuala Lumpur, 59100, Malaysia
نشط (لا يقبل مشاركين جدد)
Putrajaya
National Cancer Institute ( Site 1079), Putrajaya, Putrajaya, 62250, Malaysia
Study Coordinator, جهة اتصال, +60388925418
يقبل مشاركين
Sarawak
Sarawak General Hospital-Radiotherapy Unit ( Site 1076), Kuching, Sarawak, 93586, Malaysia
Study Coordinator, جهة اتصال, +6082276820
يقبل مشاركين
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078), Kuala Lumpur, 50586, Malaysia
Study Coordinator, جهة اتصال, +60326155810
يقبل مشاركين
Jalisco
CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103), Guadalajara, Jalisco, 44630, Mexico
نشط (لا يقبل مشاركين جدد)
Mexico City
Quemex Medical and Research ( Site 1112), Mexico City, Mexico City, 14308, Mexico
نشط (لا يقبل مشاركين جدد)
Nuevo León
Filios Alta Medicina ( Site 1106), Monterrey, Nuevo León, 64460, Mexico
نشط (لا يقبل مشاركين جدد)
Yucatán
Medical Care and Research SA de CV ( Site 1108), Mérida, Yucatán, 97070, Mexico
نشط (لا يقبل مشاركين جدد)
Centro de Investigacion Clinica de Oaxaca ( Site 1109), Oaxaca City, 68020, Mexico
نشط (لا يقبل مشاركين جدد)
Gelderland
Radboudumc-Medical Oncology ( Site 1152), Nijmegen, Gelderland, 6525 GA, Netherlands
Study Coordinator, جهة اتصال, +31 (0)24 361 0353
يقبل مشاركين
Limburg
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163), Sittard-Geleen, Limburg, 6162 BG, Netherlands
نشط (لا يقبل مشاركين جدد)
VieCuri Medisch Centrum ( Site 1173), Venlo, Limburg, 5912 BL, Netherlands
نشط (لا يقبل مشاركين جدد)
North Brabant
ETZ Elisabeth-Internal Medicine ( Site 1160), Tilburg, North Brabant, 5022 GC, Netherlands
Study Coordinator, جهة اتصال, +3113221 0210
يقبل مشاركين
North Holland
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153), Amsterdam, North Holland, 1066 CX, Netherlands
Study Coordinator, جهة اتصال, +31205122569
يقبل مشاركين
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, North Holland, 1081 HV, Netherlands
نشط (لا يقبل مشاركين جدد)
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170), Hoofddorp, North Holland, 2134 TM, Netherlands
Study Coordinator, جهة اتصال, +31232245802
يقبل مشاركين
Provincie Friesland
Medische Centrum Leeuwarden ( Site 1172), Leeuwarden, Provincie Friesland, 8934 AD, Netherlands
Study Coordinator, جهة اتصال, +31582866660
يقبل مشاركين
South Holland
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151), Schiedam, South Holland, 3118 JH, Netherlands
Study Coordinator, جهة اتصال, 003110- 4617590
يقبل مشاركين
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164), The Hague, South Holland, 2545 AA, Netherlands
Study Coordinator, جهة اتصال, +31702102143
يقبل مشاركين
Utrecht
Meander Medisch Centrum ( Site 1157), Amersfoort, Utrecht, 3813TZ, Netherlands
Study Coordinator, جهة اتصال, +003133 - 850 1189
يقبل مشاركين
Bay of Plenty
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201), Tauranga, Bay of Plenty, 3112, New Zealand
Study Coordinator, جهة اتصال, +64277033845
يقبل مشاركين
Otago
Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203), Dunedin, Otago, 9016, New Zealand
Study Coordinator, جهة اتصال, +64 3 470 9692
يقبل مشاركين
Akershus
Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227), Lørenskog, Akershus, 1474, Norway
Study Coordinator, جهة اتصال, +4767963800
يقبل مشاركين
Sor-Trondelag
St. Olavs Hospital-Kreftklinikken ( Site 1231), Trondheim, Sor-Trondelag, 7030, Norway
نشط (لا يقبل مشاركين جدد)
Østfold fylke
Sykehuset Østfold Kalnes ( Site 1228), Sarpsborg, Østfold fylke, 1714, Norway
نشط (لا يقبل مشاركين جدد)
Departamento de Junín
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258), Concepción, Departamento de Junín, 12125, Peru
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
La Libertad
Clínica Sánchez Ferrer ( Site 1261), Trujillo, La Libertad, 13009, Peru
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Aliada-Oncologìa ( Site 1257), Lima, 15036, Peru
نشط (لا يقبل مشاركين جدد)
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254), Lima, 15036, Peru
نشط (لا يقبل مشاركين جدد)
Oncosalud-Clinical Research ( Site 1260), Lima, 15036, Peru
نشط (لا يقبل مشاركين جدد)
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256), Lima, 15038, Peru
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Kuyavian-Pomeranian Voivodeship
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Study Coordinator, جهة اتصال, +48523743589
يقبل مشاركين
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316), Grudziądz, Kuyavian-Pomeranian Voivodeship, 86-300, Poland
Study Coordinator, جهة اتصال, +48566414444
يقبل مشاركين
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304), Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
نشط (لا يقبل مشاركين جدد)
Masovian Voivodeship
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310), Siedlce, Masovian Voivodeship, 08-110, Poland
Study Coordinator, جهة اتصال, +48256403301
يقبل مشاركين
West Pomeranian Voivodeship
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303), Koszalin, West Pomeranian Voivodeship, 75-581, Poland
Study Coordinator, جهة اتصال, +48943488930
يقبل مشاركين
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, West Pomeranian Voivodeship, 71-730, Poland
Study Coordinator, جهة اتصال, +48914251502
يقبل مشاركين
Świętokrzyskie Voivodeship
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318), Kielce, Świętokrzyskie Voivodeship, 25-734, Poland
Study Coordinator, جهة اتصال, +48413674811
يقبل مشاركين
Puerto Rico Medical Research Center LLC ( Site 1354), Hato Rey, 00917, Puerto Rico
نشط (لا يقبل مشاركين جدد)
Ad-Vance Medical Research-Research ( Site 1353), Ponce, 00717, Puerto Rico
Study Coordinator, جهة اتصال, 787-651-6697
يقبل مشاركين
Pan American Center for Oncology Trials - Ciudadela ( Site 1351), San Juan, 00909, Puerto Rico
نشط (لا يقبل مشاركين جدد)
Central Singapore
National University Hospital ( Site 1376), Singapore, Central Singapore, 119074, Singapore
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
National Cancer Centre Singapore ( Site 1377), Singapore, Central Singapore, 168583, Singapore
Study Coordinator, جهة اتصال, +65-64368000
يقبل مشاركين
Tan Tock Seng Hospital-Medical Oncology ( Site 1378), Singapore, Central Singapore, 308433, Singapore
Study Coordinator, جهة اتصال, +65-62566011
يقبل مشاركين
Seoul
Asan Medical Center-Oncology ( Site 1402), Songpagu, Seoul, 05505, South Korea
نشط (لا يقبل مشاركين جدد)
Seoul National University Hospital-Oncology ( Site 1401), Seoul, 03080, South Korea
Study Coordinator, جهة اتصال, +82220721672
يقبل مشاركين
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404), Seoul, 03722, South Korea
Study Coordinator, جهة اتصال, +82222288138
يقبل مشاركين
Samsung Medical Center ( Site 1405), Seoul, 06351, South Korea
Study Coordinator, جهة اتصال, +82234101767
يقبل مشاركين
Cadiz
Hospital Jerez de la Frontera ( Site 1427), Jerez de la Frontera, Cadiz, 11407, Spain
Study Coordinator, جهة اتصال, +34661753582
يقبل مشاركين
Madrid, Comunidad de
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431), Madrid, Madrid, Comunidad de, 28034, Spain
Study Coordinator, جهة اتصال, 34913368263
يقبل مشاركين
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433), Madrid, Madrid, Comunidad de, 28041, Spain
Study Coordinator, جهة اتصال, 608464547
يقبل مشاركين
Orense
Complexo Hospitalario Universitario de Ourense ( Site 1426), Ourense, Orense, 32005, Spain
Study Coordinator, جهة اتصال, +34988385471
يقبل مشاركين
Valenciana, Comunitat
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430), Valencia, Valenciana, Comunitat, 46009, Spain
Study Coordinator, جهة اتصال, +34 961114229
يقبل مشاركين
Hospital Lucus Augusti-Oncology ( Site 1432), Lugo, 27003, Spain
Study Coordinator, جهة اتصال, +34982296459
يقبل مشاركين
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428), Seville, 41013, Spain
Study Coordinator, جهة اتصال, 34955013068
يقبل مشاركين
Stockholm County
Karolinska Universitetssjukhuset Solna ( Site 1478), Stockholm, Stockholm County, 171 64, Sweden
نشط (لا يقبل مشاركين جدد)
Uppsala County
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477), Uppsala, Uppsala County, 751 85, Sweden
Study Coordinator, جهة اتصال, 0046186110000
يقبل مشاركين
Västra Götaland County
Sahlgrenska Universitetssjukhuset ( Site 1479), Gothenburg, Västra Götaland County, 413 45, Sweden
Study Coordinator, جهة اتصال, 0046313421000
يقبل مشاركين
China Medical University Hospital-Department of Urology ( Site 1503), Taichung, 40447, Taiwan
Study Coordinator, جهة اتصال, +886-4-2205-2121
يقبل مشاركين
National Cheng Kung University Hospital-Urology ( Site 1502), Tainan, 704, Taiwan
Study Coordinator, جهة اتصال, +886-6-2353535
يقبل مشاركين
National Taiwan University Hospital-Urology ( Site 1506), Taipei, 10002, Taiwan
نشط (لا يقبل مشاركين جدد)
Taipei Veterans General Hospital ( Site 1505), Taipei, 112, Taiwan
Study Coordinator, جهة اتصال, +886-2-28712121
يقبل مشاركين
Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504), Taoyuan District, 333, Taiwan
Study Coordinator, جهة اتصال, +886-3-3281200
يقبل مشاركين
Bangkok
Chulalongkorn University ( Site 1530), Bangkok, Bangkok, 10330, Thailand
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Faculty of Medicine Siriraj Hospital ( Site 1531), Bangkok, Bangkok, 10700, Thailand
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Changwat Khon Kaen
Faculty of Medicine - Khon Kaen University ( Site 1526), Muang, Changwat Khon Kaen, 40002, Thailand
Study Coordinator, جهة اتصال, +66 43 366568-9
يقبل مشاركين
Changwat Songkhla
Songklanagarind hospital ( Site 1527), Hat Yai, Changwat Songkhla, 90110, Thailand
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554), Adana, 01250, Turkey (Türkiye)
Study Coordinator, جهة اتصال, +903223444444
يقبل مشاركين
Gulhane Egitim Arastirma Hastanesi ( Site 1558), Ankara, 06010, Turkey (Türkiye)
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551), Ankara, 06230, Turkey (Türkiye)
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Memorial Ankara Hastanesi-Medical Oncology ( Site 1557), Ankara, 06520, Turkey (Türkiye)
Study Coordinator, جهة اتصال, 903122536666
يقبل مشاركين
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552), Ankara, 06800, Turkey (Türkiye)
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555), Istanbul, 34668, Turkey (Türkiye)
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553), Istanbul, 34722, Turkey (Türkiye)
Study Coordinator, جهة اتصال, +902166065200
يقبل مشاركين
Samsun Medical Park Hastanesi-medical oncology (1560), Samsun, 55200, Turkey (Türkiye)
Dilek Erdem, جهة اتصال, 905364247616, [email protected]
يقبل مشاركين
Cambridgeshire
Addenbrooke's Hospital ( Site 1605), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom
Study Coordinator, جهة اتصال, 01223216083
يقبل مشاركين
England
The Royal Cornwall Hospital ( Site 1610), Truro, England, TR1 3LJ, United Kingdom
Study Coordinator, جهة اتصال, 01872258345
يقبل مشاركين
Glasgow City
The Beatson West of Scotland Cancer Centre ( Site 1603), Glasgow, Glasgow City, G12 0YN, United Kingdom
Study Coordinator, جهة اتصال, 1-888-577-8839
يقبل مشاركين
Hammersmith and Fulham
Charing Cross Hospital-Oncology Research ( Site 1606), London, Hammersmith and Fulham, W6 8RF, United Kingdom
Study Coordinator, جهة اتصال, 0208 331 10277
يقبل مشاركين
London, City of
University College London Hospital ( Site 1612), London, London, City of, NW1 2PG, United Kingdom
نشط (لا يقبل مشاركين جدد)
The Christie NHS Foundation Trust ( Site 1608), Manchester, m20 4bx, United Kingdom
Study Coordinator, جهة اتصال, +441614463000
يقبل مشاركين